I am hearing there will be positive news soon (perhaps tomorrow) on initial trials of the Oxford Covid-19 vaccine that is backed by AstraZeneca and supported by tens of millions of pounds of government money.
The first data is due be published in the Lancet. Apparently the vaccine is generating the kind of antibody and T-cell (killer cell) response that the researchers would hope to see.
Already a subscriber? Log in
Easter flash sale:
10 issues for $1
Subscribe this Easter and get the next 10 issues of the magazine, plus website and app access, all for just $1.
- Weekly delivery of the magazine
- Unlimited access to spectator.com.au and app
- Spectator Australia podcasts and newsletters
- Full access to spectator.co.uk
Or
Comments
Easter flash sale: 10 issues for $1
Join the conversation with other Spectator Australia readers. Subscribe to leave a comment.
CLAIM OFFER 10 issues for $1Already a subscriber? Log in